Warning Letters to Telehealth providers marketing GLP-1 compounded On March 3rd, FDA sent multiple sets of warnings to 30 Telehealth companies offering GLP-1s on their websites warning them to refrain from improperly using a brand when they are not the compounder or claiming equivalency to FDA approved drugs
A clinical study involving 564 adults (BMI 30-40 kg/m2, without T2DM) found that compared with orlistat (3120 mg, weight loss of 4.1 kg), LIR (subcutaneous administration of 1.2 mg/d, 1.8 mg/d, 2.4 mg/d or 3 mg/d) had an average weight loss of 4.8-7.2 kg, the two-year extended experiment of which also showed similar results (88, 89)
Side effects were reportedly similar to GLP-1 medications, most commonly including gastrointestinal complications like nausea, vomiting and diarrhea
The timing and intensity of gastrointestinal side effects differ by product and person, so patients should choose a time that best manages their symptoms whilst maintaining consistent adherence
FAQ Is Ozempic penis a real medical condition
4 May 2016
